Discounting extreme positions: party normalization and support for the far right
Political Science Research and Methods · 2026-04 · 14 (2) · 533-541
DOI: 10.1017/psrm.2025.29 ↗Kurz gefasst
Fachartikel in der Zeitschrift Political Science Research and Methods, online erschienen am 16.04.2025. Verfasst von Laia Balcells und 2 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
When are far right parties punished for their extreme positions? We argue that the punishments of deviant position-taking are conditional on the degree to which a far right party is normalized or stigmatized in the party system. When the far right is treated as normal, the costs suffered from these parties’ extreme positions decrease, as moderate voters discount the authenticity of their commitment to such positions. We use a survey experiment to test this argument in Spain, finding evidence for discounting on the far right’s extreme anti-LGBTQ+ statements, but not on its embrace of authoritarian history. This study thus shows that normalization and stigmatization of the far right can change how its extreme positions are interpreted by voters.
Zitieren
APA
Balcells, L., Martínez, S., & vanderWilden, E. (2026). Discounting extreme positions: party normalization and support for the far right. Political Science Research and Methods, 14(2), 533-541. https://doi.org/10.1017/psrm.2025.29
Vancouver
Balcells L, Martínez S, vanderWilden E. Discounting extreme positions: party normalization and support for the far right. Political Science Research and Methods. 2026;14(2):533-541. doi:10.1017/psrm.2025.29
BibTeX
@article{Balcells2026,
author = {Balcells, Laia and Martínez, Sergi and vanderWilden, Ethan},
title = {Discounting extreme positions: party normalization and support for the far right},
journal = {Political Science Research and Methods},
year = {2026},
volume = {14},
number = {2},
pages = {533--541},
doi = {10.1017/psrm.2025.29}
}
EUVIMED